Mass rollout of weight loss jabs begins on NHS
Around 220,000 people with 'greatest need' are expected to receive Mounjaro, also known as tirzepatide and made by Lilly through the NHS over the next three years.
The drug is an antidiabetic drug which lowers blood sugar levels and and slows down how quickly food is digested.
From Monday, GPs in England will be allowed to prescribe Mounjaro to severely obese people who also suffer from a range of other health problems.
Patients previously needed to access the drugs through a special weight loss service.
But leading family doctors said some GPs have expressed concern about the additional workload linked to the rollout.
And pharmacy experts also said there could be pressure on supplies of the drug.
In the first year of the programme, the drug will be offered to people with a body mass index (BMI) score of over 40 who have at least four other health problems linked to obesity, such as type 2 diabetes; high blood pressure; heart disease; and obstructive sleep apnoea.
Estimates suggest around 1.5 million people in the UK are already taking weight loss drugs, which may have been prescribed through specialist weight loss services or via private prescription.
Dr Claire Fuller, from NHS England, said: 'This is an important next step in the rollout of weight loss drugs, with community-based services now able to offer this treatment from today.
'We urgently need to address rising levels of obesity and prioritise support for those who are experiencing severe ill health – and greater access to weight loss drugs will make a significant difference to the lives of those people.
'These drugs are an important tool alongside the range of wraparound NHS support and advice on good nutrition and increasing physical activity, which will be vital in helping some people lose weight and reduce their risk of serious long-term conditions.
'While not everyone will be eligible for weight loss drugs, it's important that anyone who is worried about the impact of their weight on their health discusses the range of NHS support available with their healthcare professional.'
Professor Kamila Hawthorne, chairwoman of the Royal College of GPs, said: 'While we recognise the potential benefits of weight loss drugs, we know many GPs are concerned about the implications of the rollout of weight loss drugs into general practice, both in terms of workload and training to appropriately initiate and manage these treatments.
'The college shares these concerns, which is why we were pleased NHS England suggested a phased roll-out of Mounjaro as a treatment for weight loss. As and when this is escalated, appropriate resourcing for general practice – including access to 'wraparound' services – and training for GPs must follow.
GLP-1s like #Ozempic, #Saxenda, #Wegovy, or #Mounjaro are not an easy #weightloss hack.
Find out more about:🔵what they are ❓🔵how they're used 💊🔵who they help 💪
🔗Learn more: https://t.co/GY4a7VRAgF pic.twitter.com/Agiav8ryfU
— EU Medicines Agency (@EMA_News) January 4, 2025
She added: 'GPs and our teams are already working under intense workload and workforce pressures, and this must be factored into this rollout in order to guarantee it can be delivered safely.
'More widely, whilst weight loss medications have a lot of potential benefits for patients who are struggling to lose weight and who meet all the clinical criteria for a prescription, they mustn't be seen as a 'silver bullet' to aid weight loss.
'We also need to see a focus on prevention, stopping people becoming overweight in the first place so they don't require a medical intervention later.'
Dr Hawthorne said there is no 'one size fits all approach' and that the rollout of the jabs should not 'come at the expense of other weight loss service'.
She continued: 'The roll-out of weight loss medications in the NHS will need to be consistently evaluated to ensure that there is evidence that these prescriptions are of long-term benefit to patients.'
Olivier Picard, chairman of the National Pharmacy Association, said: 'The demand for weight loss jabs continues to rise sharply, and more GPs have been directing patients back to pharmacies after initial inquiries, to access these treatments privately.
'As the NHS is now moving to implement National Institute for Health and Care Excellence (Nice) guidance, and tirzepatide becomes prescribable to more patients, we expect to see prescription volumes increase rapidly.
'However, NHS provision won't meet demand straight away, so we fully expect that many people will continue seeking it privately from a pharmacy.
'Pharmacists are experts in medication and many of us have lots of experience delivering weight loss injections as part of a package of care including lifestyle advice.
'We are well placed to help roll out weight loss treatment on the NHS, with the right funding to support it.
'The biggest concern we have is that prescribing these medications alone misses the point.
'They should be part of a comprehensive weight management strategy – combining lifestyle coaching, exercise, and nutritional guidance. In reality, many GPs lack the bandwidth to deliver the level of support needed to ensure proper understanding and follow-up.
'As a result, we could end up in a situation where patients are prescribed the medication, lose weight, and then experience rebound weight gain once the course ends – simply because the foundational lifestyle changes weren't addressed.'
Around 29% of the adult population in the UK is obese.
Health Secretary Wes Streeting said: 'Obesity is now one of the leading causes of ill health, costing the NHS billions. Yet we now have the science, technology, and knowledge to end the obesity epidemic, if we seize this opportunity.
'Obesity jabs are used by 1.5 million people in the UK, mainly through private prescriptions. The NHS was founded on a promise to 'universalise the best', and this Government is determined to bring revolutionary modern treatments to everyone who needs them, not just those who can afford to pay.
'This rollout is an important step in making these medicines more widely available, and beginning to shift the focus of healthcare from sickness to prevention, which our forthcoming 10-year plan will deliver.'

Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
11 minutes ago
- Yahoo
Pharmacy warning of unsustainable demand for weight loss medication
The National Pharmacy Association (NPA) has issued a warning that the burgeoning demand for weight loss injections may be unsustainable, citing a significant mismatch between public interest and clinical suitability for the treatments. The NPA, which represents over 6,000 independent community pharmacies, highlighted this concern. A poll commissioned by the association revealed that 21 per cent of respondents had attempted to access weight loss treatments in the past year, either online or directly from a pharmacy. This figure surged to 35 per cent among 16 to 34-year-olds, contrasting sharply with just seven per cent of those over 55. There were also 41% who agreed they would opt for weight loss treatments on the NHS if they were made available to them. This figure rose to 64% among 25 to 34-year-olds, despite many of these patients being unlikely to be clinically eligible. The NPA says the poll, in which 2,002 people were interviewed, reflects an increasing demand for private and NHS weight loss services. NPA chairman Olivier Picard said: 'Weight loss jabs are one of the biggest drug innovations this century, but growing demand for weight loss treatment highlights the need to make sure this is appropriate for those who want it. 'It's clear from this polling that many more people are interested in getting weight loss jabs than would actually be suitable for treatment. 'We want to make sure supplies are carefully managed so that those in most clinical need can benefit from weight loss medication.' Spiralling demand, fuelled partly by social media, could see people being tempted to resort to unregulated online suppliers instead of regulated pharmacies staffed by medical professionals, they fear. Online suppliers may not be offering weight loss jabs alongside a structured programme aimed at helping them change their behaviour. Wegovy and Mounjaro are among a number of drugs that are recommended to help tackle obesity on the NHS. Mounjaro and Wegovy are licensed by the Medicines and Healthcare products Regulatory Agency (MHRA) for use in patients with a BMI of over 30 or between 27 and 30 but with a weight-related co-morbidity. This occurs when an individual who has obesity develops another medical condition due to their weight. The NHS currently rolls out Mounjaro to patients with a BMI of over 40 and at least four co-morbidities, the NPA says. The NPA is calling for new regulations to protect patients buying weight loss medication online, so there is a full two-way consultation and all relevant historical medical records are reviewed before the treatment is prescribed. They are waiting for more details about the role pharmacies could play in the rollout of the NHS weight management programme. At least 85% of weight loss medication prescriptions were made by pharmacies in April this year, the NPA estimates. Mr Picard said: 'Pharmacists are experts in medication and many have extensive experience delivering weight loss injections as part of a package of care, including lifestyle advice. 'Pharmacies are well placed to help roll this treatment out on the NHS, and help people make the best use of these powerful medicines.'
Yahoo
2 hours ago
- Yahoo
Brains Aged Faster In 2021–2022: What Did The Pandemic Do To Us?
A new study suggests that the pandemic may have had a significant impact on our brains, whether or not we contracted COVID-19. Leveraging an extensive database of brain scans, British researchers say that people's brains showed accelerated aging during 2021 and 2022, including signs of shrinkage. While people who were infected with COVID also showed cognitive decline, like slower processing speed, the study was notable because it said even the non-infected were likely to experience harm to their brain. While the study did not delve into the exact causes of the accelerated aging, the study's first author, Ali-Reza Mohammadi-Nejad, a neuroimaging researcher at the University of Nottingham, theorizes that it may have been the result of stress and other factors. 'But it is likely that the cumulative experience of the pandemic—including psychological stress, social isolation, disruptions in daily life, reduced activity and wellness—contributed to the observed changes… In this sense, the pandemic period itself appears to have left a mark on our brains, even in the absence of infection,' said Mohammadi-Nejad, per NBC. The researchers found that males and 'those from more socioeconomically deprived backgrounds' experienced the most significant brain aging. Overall, the pandemic was thought to be linked to a 5.5-month acceleration in the aging process. This is not the first time researchers have reached similar conclusions. Last year, a previous study found that teenagers experienced dramatic brain aging during the pandemic. Notably, the study suggested that girls' brains aged 4.2 years faster and boys' brains aged 1.3 years faster, on average. The latest study does not indicate whether the structural changes identified in individuals who have never contracted COVID will result in any noticeable changes in brain function. Nor does the study confirm whether the physical changes will persist over the long term, says Adam Brickman, a professor of neuropsychology at Columbia University Vagelos College of Physicians and Surgeons, who was not involved in the study.
Yahoo
3 hours ago
- Yahoo
John Swinney pays tribute to Scottish woman who lost battle with anorexia aged 20
First Minister John Swinney has paid tribute to a young Scottish constituent who sadly lost her battle with anorexia earlier this year. The first minister attended a charity park run, which was organised by the family of Rachel Bywater from Aberfeldy, to raise funds for BEAT, the UK's leading charity supporting those affected by eating disorders, reports The Record. Swinney joined the family of Rachel, who sadly died on May 17 this year aged just 20 years old, at the event which has raised an amazing £7,500 for the charity. READ MORE: Netflix viewers rush to watch 'compelling' BBC drama series set in Edinburgh READ MORE: Edinburgh's first 'queer cafe' announces closure as owners say 'this is only the beginning' The MSP for Perthshire North shared a snap of the group together sporting their, 'Run for Rachel' t-shirts and wrote: "A special privilege to join the family of Rachel Bywater - one of my constituents who faced an eating disorder and sadly died recently aged only 20 - to run a 5k and raise funds for Beat (Eating Disorders). "Wonderful to see so many in the #Aberfeldy community supporting today." Her father Dave Bywater added: "Thank you John, it was great to have your support and that of the community. 'I hope everyone who reads these posts can realise there is a family behind this who are suffering a tragic loss, and ignore the offensive responses you have received." Join Edinburgh Live's Whatsapp Community here and get the latest news sent straight to your messages. Ahead of the event her family wrote: "We will be installing a new bench on the River Bank for Rachel Bywater, who very sadly passed away on May 17th this year. "To mark the occasion a fund raiser will be held on the Sunday to raise funds for BEAT (Eating Disorders). All you have to do is walk, jog or run 1, 2 or 3 laps of the FeldyRoo Fitness Trail. "The choice is yours, all we want is everyone to get involved. You can fill in an entry form and pick up sponsorship form at any of the pubs - Fountain, Black Wach or Schiehallion. "Entry is totally free but raised sponsorship or donations on the day would be really appreciated no matter how little or large."